CY1119869T1 - Αντικαρκινικος παραγοντας και μεθοδος προβλεψης θεραπευτικου αποτελεσματος για ασθενεις με κολοορθικο καρκινο μεταλλαξης kras - Google Patents
Αντικαρκινικος παραγοντας και μεθοδος προβλεψης θεραπευτικου αποτελεσματος για ασθενεις με κολοορθικο καρκινο μεταλλαξης krasInfo
- Publication number
- CY1119869T1 CY1119869T1 CY20181100119T CY181100119T CY1119869T1 CY 1119869 T1 CY1119869 T1 CY 1119869T1 CY 20181100119 T CY20181100119 T CY 20181100119T CY 181100119 T CY181100119 T CY 181100119T CY 1119869 T1 CY1119869 T1 CY 1119869T1
- Authority
- CY
- Cyprus
- Prior art keywords
- cancer
- kras
- prediction
- patients
- patient
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 230000001093 anti-cancer Effects 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 206010064571 Gene mutation Diseases 0.000 abstract 2
- 101150105104 Kras gene Proteins 0.000 abstract 2
- 238000002512 chemotherapy Methods 0.000 abstract 2
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 239000012472 biological sample Substances 0.000 abstract 1
- KGHYQYACJRXCAT-UHFFFAOYSA-N tipiracil hydrochloride Chemical compound Cl.N1C(=O)NC(=O)C(Cl)=C1CN1C(=N)CCC1 KGHYQYACJRXCAT-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011177838 | 2011-08-16 | ||
| PCT/JP2012/070745 WO2013024865A1 (ja) | 2011-08-16 | 2012-08-15 | Ｋｒａｓ遺伝子変異型の結腸直腸癌患者に対する抗腫瘍剤及び治療効果予測方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1119869T1 true CY1119869T1 (el) | 2018-06-27 |
Family
ID=47715182
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20181100119T CY1119869T1 (el) | 2011-08-16 | 2018-01-31 | Αντικαρκινικος παραγοντας και μεθοδος προβλεψης θεραπευτικου αποτελεσματος για ασθενεις με κολοορθικο καρκινο μεταλλαξης kras |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9371380B2 (enExample) |
| EP (1) | EP2746404B1 (enExample) |
| JP (1) | JP5832541B2 (enExample) |
| KR (1) | KR101693090B1 (enExample) |
| CN (1) | CN103764847B (enExample) |
| AU (1) | AU2012295841B2 (enExample) |
| CY (1) | CY1119869T1 (enExample) |
| DK (1) | DK2746404T3 (enExample) |
| ES (1) | ES2659264T3 (enExample) |
| HR (1) | HRP20180130T1 (enExample) |
| HU (1) | HUE035347T2 (enExample) |
| LT (1) | LT2746404T (enExample) |
| NO (1) | NO2746404T3 (enExample) |
| PL (1) | PL2746404T3 (enExample) |
| PT (1) | PT2746404T (enExample) |
| RS (1) | RS56911B1 (enExample) |
| RU (1) | RU2585528C2 (enExample) |
| SI (1) | SI2746404T1 (enExample) |
| SM (1) | SMT201800108T1 (enExample) |
| TW (1) | TWI550089B (enExample) |
| WO (1) | WO2013024865A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2998742A4 (en) * | 2013-05-17 | 2017-01-18 | Taiho Pharmaceutical Co., Ltd. | Therapeutic effect prediction method for colorectal cancer patient in whom expression of tk1 protein has increased |
| EP3328394A4 (en) | 2015-07-30 | 2019-03-13 | ModernaTX, Inc. | CONCATEMEE peptide epitope RNAs |
| UA123403C2 (uk) * | 2016-02-05 | 2021-03-31 | Тайхо Фармасьютікал Ко., Лтд. | Спосіб лікування хворих на рак з тяжкою нирковою недостатністю |
| AU2017397458B2 (en) * | 2017-02-01 | 2025-07-10 | Modernatx, Inc. | RNA cancer vaccines |
| WO2018170245A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1849470T5 (pl) | 2005-01-26 | 2024-06-10 | Taiho Pharmaceutical Co., Ltd. | Lek przeciwrakowy zawierający alfa,alfa,alfa-trifluorotymidynę i inhibitor fosforylazy tymidynowej |
| US7799783B2 (en) | 2005-01-26 | 2010-09-21 | Taiho Pharmaceutical Co., Ltd. | Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor |
-
2012
- 2012-08-15 KR KR1020147006642A patent/KR101693090B1/ko active Active
- 2012-08-15 PL PL12824342T patent/PL2746404T3/pl unknown
- 2012-08-15 EP EP12824342.5A patent/EP2746404B1/en active Active
- 2012-08-15 CN CN201280040055.4A patent/CN103764847B/zh active Active
- 2012-08-15 JP JP2013529023A patent/JP5832541B2/ja active Active
- 2012-08-15 DK DK12824342.5T patent/DK2746404T3/en active
- 2012-08-15 SM SM20180108T patent/SMT201800108T1/it unknown
- 2012-08-15 US US14/238,569 patent/US9371380B2/en active Active
- 2012-08-15 LT LTEP12824342.5T patent/LT2746404T/lt unknown
- 2012-08-15 AU AU2012295841A patent/AU2012295841B2/en active Active
- 2012-08-15 WO PCT/JP2012/070745 patent/WO2013024865A1/ja not_active Ceased
- 2012-08-15 NO NO12824342A patent/NO2746404T3/no unknown
- 2012-08-15 SI SI201231194T patent/SI2746404T1/en unknown
- 2012-08-15 HR HRP20180130TT patent/HRP20180130T1/hr unknown
- 2012-08-15 ES ES12824342.5T patent/ES2659264T3/es active Active
- 2012-08-15 RU RU2014109999/10A patent/RU2585528C2/ru active
- 2012-08-15 HU HUE12824342A patent/HUE035347T2/en unknown
- 2012-08-15 RS RS20180124A patent/RS56911B1/sr unknown
- 2012-08-15 PT PT128243425T patent/PT2746404T/pt unknown
- 2012-08-16 TW TW101129724A patent/TWI550089B/zh active
-
2018
- 2018-01-31 CY CY20181100119T patent/CY1119869T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2013024865A1 (ja) | 2015-03-05 |
| JP5832541B2 (ja) | 2015-12-16 |
| ES2659264T3 (es) | 2018-03-14 |
| NO2746404T3 (enExample) | 2018-05-05 |
| TW201319257A (zh) | 2013-05-16 |
| WO2013024865A1 (ja) | 2013-02-21 |
| RU2585528C2 (ru) | 2016-05-27 |
| TWI550089B (zh) | 2016-09-21 |
| EP2746404B1 (en) | 2017-12-06 |
| EP2746404A1 (en) | 2014-06-25 |
| SMT201800108T1 (it) | 2018-05-02 |
| RU2014109999A (ru) | 2015-10-10 |
| SI2746404T1 (en) | 2018-04-30 |
| DK2746404T3 (en) | 2018-01-15 |
| HK1197086A1 (zh) | 2015-01-02 |
| HRP20180130T1 (hr) | 2018-04-06 |
| CN103764847B (zh) | 2016-05-11 |
| HUE035347T2 (en) | 2018-05-02 |
| PT2746404T (pt) | 2018-01-10 |
| PL2746404T3 (pl) | 2018-04-30 |
| CN103764847A (zh) | 2014-04-30 |
| KR20140057328A (ko) | 2014-05-12 |
| AU2012295841B2 (en) | 2015-12-10 |
| RS56911B1 (sr) | 2018-05-31 |
| EP2746404A4 (en) | 2015-04-08 |
| US9371380B2 (en) | 2016-06-21 |
| AU2012295841A1 (en) | 2014-04-03 |
| LT2746404T (lt) | 2018-04-25 |
| US20140213602A1 (en) | 2014-07-31 |
| KR101693090B1 (ko) | 2017-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1119869T1 (el) | Αντικαρκινικος παραγοντας και μεθοδος προβλεψης θεραπευτικου αποτελεσματος για ασθενεις με κολοορθικο καρκινο μεταλλαξης kras | |
| CY1125190T1 (el) | Χρηση ομαδων γονιδιων fgfr μεταλλαγματων στην εξακριβωση του εαν καρκινοπαθεις θα αποκρινονται σε αγωγη me fgfr αναστολεα | |
| CY1123883T1 (el) | Ανθρωποποιημενα αντισωματα κατα της liv-1 και χρηση αυτων για τη θεραπευτικη αντιμετωπιση του καρκινου | |
| CY1124654T1 (el) | Αντιδραστηριο μοριακης ανιχνευσης/διαγνωσης για ογκους | |
| CY1124928T1 (el) | Αναστολεις πυραζολυλο κινοξαλινο κινασης | |
| CY1125421T1 (el) | Ριβονουκλεϊκα οξεα που περιεχουν ν1-μεθυλο- ψευδοουρακιλες και χρησεις αυτων | |
| CY1122707T1 (el) | Ετεροκυκλικοι αναστολεις γλουταμινασης | |
| CY1119799T1 (el) | Συνδυασμος αντισωματων anti-kir και αντισωματων anti-pd-1 για αγωγη καρκινου | |
| CY1120421T1 (el) | Ενωσεις και μεθοδοι για διαμορφωση κινασων και ενδειξεις αυτων | |
| CY1122144T1 (el) | Αιθερες αρυλιου και χρησεις εξ αυτων | |
| MX343327B (es) | Ensayos para detectar autoanticuerpos contra farmacos anti-tnfa. | |
| CY1124140T1 (el) | Διαγνωστικοi δεικτες για την θεραπευτικη αντιμετωπιση υπερπλαστικων διαταραχων των κυτταρων με αναστολεα τελομερασης | |
| CY1119251T1 (el) | Θεραπεια συνδυασμου ενος αφουκοζυλιωμενου αντισωματος cd20 με μπενδαμουστινη | |
| CY1119794T1 (el) | Ενωσεις αναστολεων ε-σελεκτινης | |
| CY1120556T1 (el) | Δικυκλικα ετεροκυκλα ως αναστολεις fgfr | |
| CY1116231T1 (el) | ΑΛΑΤΑ ΥΠΟΚΑΤΕΣΤΗΜΕΝΗΣ 2,3-ΔIYΔPOΪMIΔAZO[l,2-C] ΚΙΝΑΖΟΛΙΝΗΣ | |
| EP2114990A4 (en) | EXPRESSION PROFILES OF GENES AND PROTEINS ASSOCIATED WITH THE THERAPEUTIC EFFICACY OF EGFR-TK INHIBITORS | |
| MA32547B1 (fr) | Antagonistes specifiques du recepteur fgf-r4 | |
| EA201391074A1 (ru) | Профили экспрессии генов рака толстой кишки и способы применения | |
| CY1118157T1 (el) | Εκλεκτικοι αναστολεις γλυκοσιδασης και χρησεις αυτων | |
| EP2689386A4 (en) | PERSONALIZED DEVICES, METHODS AND SYSTEMS FOR PURCHASING AT THE BUTTON PRESSURE | |
| EA201391351A1 (ru) | Способы повышения эффективности folr1 терапии рака | |
| CY1122156T1 (el) | Αντισωματα κατα του σχετιζομενου με τον νεφρο αντιγονου 1 και αντιγονοδεσμευτικα θραυσματα αυτων | |
| EA201400117A1 (ru) | Способы и нуклеиновые кислоты для определения прогноза у больных раком | |
| JOP20140128B1 (ar) | تركيبة علاجية تشتمل على مثبط b_raf ومثبط ثان |